Table 2.
Clinical factors predicting prostate cancer (PCa) progression in 901 patients treated with robot-assisted radical prostatectomy
| Number of cases (%) | No PCa progression | PCa progression | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|---|---|
| 742 (82.4) | 159 (17.6) | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age < 70 years | 544 (73.3) | 114 (71.7) | Ref | Ref | ||
| Age ≥ 70 years | 198 (26.7) | 45 (28.3) | 1.276 (0.901–1.806) | 0.178 | 1.230 (0.861–1.757) | 0.256 |
| Body mass index; BMI (kg/m^2) | 25.8 (23.9–28.1) | 25.6 (24–28) | 0.991 (0.942–1.043) | 0.730 | 0.976 (0,929–1,026) | 0.336 |
| ASA 1 | 59 (8.0) | 18 (11.3) | Ref | Ref | ||
| ASA 2 | 615 (82.9) | 128 (80.5) | 0.671 (0.418–1.077) | 0.098 | 0.920 (0.566–1.495) | 0.737 |
| ASA 3 | 68 (9.2) | 13 (8.2) | 0.762 (0.379–1.532) | 0.445 | 0.782 (0.384–1.591) | 0.497 |
| PV | 40 (30–50) | 39 (30–50) | 1.003 (0.994–1.012) | 0.550 | 1.003 (0.993–1.013) | 0.583 |
| PSA < 10 ng/mL | 631 (85) | 100 (62.9) | Ref | Ref | ||
| PSA: 10–20 ng/mL | 92 (12.4) | 40 (25.2) | 2.524 (1.746–3.650) | < 0.0001 | 1.935 (1.301–2.879) | < 0.0001 |
| PSA > 20 ng/mL | 19 (2.6) | 19 (11.9) | 4.291 (2.620–7.030) | < 0.0001 | 2.420 (1.397–4.192) | 0.002 |
| BPC < 50% | 572 (77.1) | 96 (60.4) | Ref | Ref | ||
| BPC ≥ 50% | 170 (22.9) | 63 (39.6) | 2.225 (1.616–3.062) | < 0.0001 | 1.654 (1.164–2.353) | 0.005 |
| ISUP 1 | 300 (40.4) | 43 (27) | Ref | Ref | ||
| ISUP 2/3 | 366 (49.3) | 80 (50.3) | 2.653 (1.823–3.863) | < 0.0001 | 2.473 (1.685–3.630) | < 0.0001 |
| ISUP 4/5 | 76 (10.2) | 36 (22.6) | 4.447 (2.843–6.954) | < 0.0001 | 2.480 (1.516–4.056) | < 0.0001 |
| cT1 | 456 (61.5) | 86 (54.1) | Ref | Ref | ||
| cT2/3 | 286 (38.5) | 73 (45.9) | 1.902 (1.389–2.605) | < 0.0001 | 1.522 (1.098–2.110) | 0.012 |
| cN0 | 708 (95.4) | 143 (89.9) | Ref | Ref | ||
| cN1 | 34 (4.6) | 16 (10.1) | 3.300 (1.959–5.559) | < 0.0001 | 2.183 (1.257–3.794) | 0.006 |
see Table 1; HR Hazard ratio, CI confidence interval